
Regeneron Pharmaceuticals receives FDA approval for Veopoz to treat CHAPLE disease, a rare blood condition. Veopoz, priced at $34,615.38 per vial, is the first FDA-approved treatment for this ailment, set to be available in Q3 2023. CHAPLE disease affects very few patients globally. The approval also addresses concerns regarding a higher dose of Regeneron's eye disease drug, Eylea. The FDA will decide on the 8mg Eylea dose soon
Like
Save
Share